Your Voice Patient Survey
This is your chance to improve access to osteoporosis medications in BC.
The survey is now live, available only from October 20 to November 17, 2021.
Go to the Your Voice website to take the survey.
Waiting room poster for health care offices
See announcement from Osteoporosis Canada
Read Understanding Pharmacare 101 to understand how Pharmacare Special Authority works in our province of BC
Provide patients with these template letters
Letter from Osteoporosis Canada for patients and caregivers
Letter from Ministry of Health
Subject: [External] Advance notification of Therapeutic Review of Drugs Used for the Primary Prevention of Osteoporosis
This is an advance notification that the Ministry of Health will soon be collecting patient input for our therapeutic review of drugs used for the primary prevention of osteoporosis. The drugs included in our review are as follows:
Oral bisphosphonates: etinodrate, alendronate 10mg and 70mg, alendronate/cholecalciferol, and risedronate;
Intravenous (IV) bisphosphonate: zoledronic acid;
Selective estrogen receptor modulators: raloxifene;
Oral bisphosphonates: generics;
Intravenous (IV) bisphosphonate: Aclasta®, generics;
Selective estrogen receptor modulators: Evista® and generics:
Drugs used for: the primary prevention of osteoporosis
Tentative Dates for Input: Wednesday, October 20, 2021 to Wednesday, November 17, 2021 AT MIDNIGHT
You will receive an additional notification once the survey is available for input.
Once the survey is available for input we will also post a PDF of the survey questions so that patients, caregivers, and patient groups can review the questions before filling in the survey, itself.
Once the survey is posted, you can provide input by visiting our website at: http://www.health.gov.bc.ca/pharmacare/yourvoice/ .
Pharmaceutical, Laboratory & Blood Services Division - B.C. Ministry of Health